News

Details

Published: 07 January 2019

• portfolio-news

AYOXXA today announced that it has signed a research agreement with one of the leading pharmaceutical companies. The agreement targets the development of low volume and high sensitivity multiplex assays for aqueous humor protein profiling for biomarker identification and validation in support of drug discovery in ophthalmology. The collaboration reflects an initial phase of a multi study plan in the field of ophthalmology and is a further step to establish AYOXXA LUNARISTM system as the standard for biomarker identification and validation in translational proteomics. 

Details

Published: 26 November 2018

• portfolio-news

Adrenomed AG, the vascular integrity company, today announced the closing of a €24 million series D financing round. The new funds will be invested in the clinical development program of lead product candidate Adrecizumab. Adrecizunab is currently tested in a phase II clinical trial in patients with early septic shock and elevated plasma Adrenomedullin concentrations (bio-ADM). 

Details

Published: 06 November 2018

• portfolio-news

The recently completed Phase 2 clinical trial was designed to assess the safety, tolerability and immunogenicity of its lead vaccine candidate (MV-CHIK) to protect against Chikungunya fever, a mosquito-transmitted disease that has no current treatment or prevention options. The primary endpoint, defined as the presence of neutralizing antibodies against Chikungunya, four weeks after administration of one or two MV-CHIK injections, was met across all treatment groups.